AIMS: Ca(2+) waves are thought to be important in the aetiology of ventricular tachyarrhythmias. There have been conflicting results regarding whether flecainide reduces Ca(2+) waves in isolated cardiomyocytes. We sought to confirm whether flecainide inhibits waves in the intact cardiomyocyte and to elucidate the mechanism. METHODS AND RESULTS: We imaged spontaneous sarcoplasmic reticulum (SR) Ca(2+) release events in healthy adult rat cardiomyocytes. Variation in stimulation frequency was used to produce Ca(2+) sparks or waves. Spark frequency, wave frequency, and wave velocity were reduced by flecainide in the absence of a reduction of SR Ca(2+) content. Inhibition of I(Na) via alternative pharmacological agents (tetrodotoxin, propafenone, or lidocaine) produced similar changes. To assess the contribution of I(Na) to spark and wave production, voltage clamping was used to activate contraction from holding potentials of -80 or -40 mV. This confirmed that reducing Na(+) influx during myocyte stimulation is sufficient to reduce waves and that flecainide only causes Ca(2+) wave reduction when I(Na) is active. It was found that Na(+)/Ca(2+)-exchanger (NCX)-mediated Ca(2+) efflux was significantly enhanced by flecainide and that the effects of flecainide on wave frequency could be reversed by reducing [Na(+)](o), suggesting an important downstream role for NCX function. CONCLUSION: Flecainide reduces spark and wave frequency in the intact rat cardiomyocyte at therapeutically relevant concentrations but the mechanism involves I(Na) reduction rather than direct ryanodine receptor (RyR2) inhibition. Reduced I(Na) results in increased Ca(2+) efflux via NCX across the sarcolemma, reducing Ca(2+) concentration in the vicinity of the RyR2.
AIMS: Ca(2+) waves are thought to be important in the aetiology of ventricular tachyarrhythmias. There have been conflicting results regarding whether flecainide reduces Ca(2+) waves in isolated cardiomyocytes. We sought to confirm whether flecainide inhibits waves in the intact cardiomyocyte and to elucidate the mechanism. METHODS AND RESULTS: We imaged spontaneous sarcoplasmic reticulum (SR) Ca(2+) release events in healthy adult rat cardiomyocytes. Variation in stimulation frequency was used to produce Ca(2+) sparks or waves. Spark frequency, wave frequency, and wave velocity were reduced by flecainide in the absence of a reduction of SR Ca(2+) content. Inhibition of I(Na) via alternative pharmacological agents (tetrodotoxin, propafenone, or lidocaine) produced similar changes. To assess the contribution of I(Na) to spark and wave production, voltage clamping was used to activate contraction from holding potentials of -80 or -40 mV. This confirmed that reducing Na(+) influx during myocyte stimulation is sufficient to reduce waves and that flecainide only causes Ca(2+) wave reduction when I(Na) is active. It was found that Na(+)/Ca(2+)-exchanger (NCX)-mediated Ca(2+) efflux was significantly enhanced by flecainide and that the effects of flecainide on wave frequency could be reversed by reducing [Na(+)](o), suggesting an important downstream role for NCX function. CONCLUSION: Flecainide reduces spark and wave frequency in the intact rat cardiomyocyte at therapeutically relevant concentrations but the mechanism involves I(Na) reduction rather than direct ryanodine receptor (RyR2) inhibition. Reduced I(Na) results in increased Ca(2+) efflux via NCX across the sarcolemma, reducing Ca(2+) concentration in the vicinity of the RyR2.
Ca2+ waves are thought to be important in the aetiology of a number
of different forms of ventricular tachyarrhythmia, particularly in heart failure
(HF) and catecholaminergic polymorphic ventricular tachycardia (CPVT).[1] The mechanisms for these
arrhythmias are thought to be associated with elevated levels of spontaneous
sarcoplasmic reticulum (SR) Ca2+ release for a given SR
load.[1,2] In other words, the threshold
SR Ca2+ content for store-overload-induced Ca2+
release is reduced in both CPVT and in HF,[2-4] leading
to Ca2+ spark and wave generation. In CPVT, this is related to
mutations of the cardiac ryanodine receptor (RyR2) or absence of calsequestrin,
whereas in HF this may relate to post-translational modification of the RyR2, such
as hyperphosphorylation.[2,5]There has been recent interest in pharmacological agents which target potentially
arrhythmogenic Ca2+ waves. Flecainide, a drug that has been used
for many years clinically for its sodium current
(INa)-reducing properties, has shown efficacy in the
treatment of CPVT patients.[6,7] However, the mechanism of
action producing this clinical effect is debated. In a mouse model of CPVT,
Knollmann and colleagues[7-9] have
shown that flecainide reduces Ca2+ wave frequency in both intact
and permeabilized myocytes and have provided evidence that this is related to a
direct action on the RyR2 via an open-state block of the channel. In contrast,
similar experiments in both intact and permeabilized myocytes have been repeated by
Liu et al.[10] (although in a different mouse model of CPVT), and no effect on
Ca2+ wave frequency was found despite similar experimental
conditions. The conclusion of Liu et al. was that the reduction in
INa caused by flecainide affected the threshold
potential, which decreased the number of spontaneous action potentials triggered by
delayed after-depolarizations (DADs) associated with Ca2+
waves.Our aim in this study was to assess whether flecainide had an effect on
Ca2+ sparks and waves and to further investigate the
mechanism. We observed SR Ca2+ release events in intact rat
ventricular cardiomyocytes from healthy rats. We show via a variety of
pharmacological and electrophysiological interventions that a reduction in
INa during cellular contraction can reduce the
frequency of Ca2+ sparks and waves in the diastolic period. We
also show that, in the case of flecainide, the INa
blocking effects are more relevant to wave reduction under our experimental
conditions than RyR2 stabilization. Finally, we explore the mechanism of this wave
reduction. We conclude that the most likely explanation for the reduction in the
presence of INa blockade is that it prevents an increase
in [Na+]i resulting in more effective
Na+/Ca2+-exchanger (NCX)-mediated efflux of
Ca2+.
Methods
Ventricular myocyte isolation and Ca2+ imaging
Extended methods are available in Supplementary material online. All animal surgical procedures
and peri-operative management were carried out in accordance with the Guide for
the Care and Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication, 8th Edition, 2011) under assurance number A5634-01.
Imperial College Ethical Review Committee authorized the project licence. Rats
were sacrificed by cervical dislocation following exposure to 5%
isoflurane until righting reflex was lost. Cardiac myocytes were enzymatically
isolated from the left ventricle of healthy adult male Sprague Dawley rats by
the Langendorff perfusion technique.[11] Intact isolated myocytes were loaded with the
Ca2+-sensitive fluorescent dyes fluo-4AM or
fura-2AM prior to imaging.
Intracellular Ca2+ measurements
Experiments were performed with cells undergoing superfusion at 37°C.
Transients were assessed during steady-state external field stimulation at 0.5
Hz. Sparks were recorded following cessation of 0.5 Hz contraction during the
last 10 s of a 25 s period of quiescence. Diaz et al.[12] have previously shown
that [Na+]i rises when quiescent cardiomyocytes are
stimulated and that this, together with higher SR Ca2+
content, was correlated with increased wave frequency. Similarly, in our
experiments, a higher stimulation frequency was associated with an increased
wave frequency in a subsequent quiescent period, presumably for similar reasons
(see Supplementary material online, A). This preliminary series of
experiments established that 30 s of 5 Hz stimulation (after 2 min of stable
contraction at 0.5 Hz) would consistently produce Ca2+ waves
in normal tyrode (NT) in the quiescent interval.
Voltage clamp technique
Cells were voltage-clamped using an amphotericin-perforated patch technique. The
switch clamp technique [with an Axoclamp 2B amplifier (Axon Instruments)] was
used to overcome any changes in access resistance that may have occurred over
the course of an experiment. Myocytes were clamped at −80 or −40
mV and depolarized to 0 mV for 100 ms to cause contraction with and without
INa activation, respectively. A 5 Hz stimulation
train was followed by a quiescent period during which the membrane potential was
held at −80 mV for 30 s, and wave frequency was assessed as before.
Data-pairing and statistical analysis
Where possible, data were obtained in a paired fashion and drugs applied or
washed off in the form of a cross-over protocol alternating from cell to cell
(Figure A). For example, the first cell had the
drug applied following a control period, whereas the next cell had drug applied
first with subsequent wash-off.Experimental protocol and effects of flecainide on
Ca2+ transients and Ca2+
sparks. (A) Experimental flowchart to explain
cross-over protocol used in experiments. Fifty per cent of cells had
NT applied first with drug wash-on, whereas 50% had drug
applied first and subsequently washed-off. (B)
Stimulated Ca2+ transients were assessed using the
ratiometric dye fura-2 calibrated to give
[Ca2+]i. Transient amplitude was
not changed in the presence of 5 μM flecainide
(n = 30 cells, P
= 0.19). (C) 20 mM caffeine in
0Na+/0Ca2+ solution was used
to assess SR Ca2+ load following a 5 Hz
contraction train. The amplitude was unchanged in the presence of 5
µM flecainide (n = 13 cells in each
group, P = 0.96 by Student's
t-test). (D) Spark frequency
was reduced following flecainide application (n
= 24 cells, P = 0.002).
(E) Representative line-scans showing a
reduction in spark frequency with flecainide. The same cell is shown
before and after flecainide application.As a result, paired t-tests were used for significance testing
unless stated. Depending on the data, Student's t-tests,
log-rank, and repeated-measures analysis of variance (ANOVA) were also used to
assess effects. Results were considered statistically significant if the
P-value was <0.05. Unless otherwise indicated,
results are expressed as mean ± standard error of the mean.
Results
Flecainide has no effect on the Ca2+ transient or SR
Ca2+ load
We first assessed the effect of 5 µM flecainide on the amplitude of
Ca2+ transients evoked by external field stimulation at
0.5 Hz. Stimulation continued at the same rate during the 5 min wash-on or
wash-off periods. Ca2+ transient amplitude did not change
significantly in the presence of flecainide (Figure ). Similarly, transient
morphology was unchanged (see Supplementary material online, B and C). SR load
was measured using a 20 mM caffeine spritz in
0Na+/0Ca2+ solution following field
stimulation at 5 Hz to mimic conditions used to assess waves
(Figure ) and was unchanged by flecainide.
Flecainide reduces Ca2+ spark and wave frequency and
Ca2+ wave velocity
Spark frequency was significantly reduced with exposure to flecainide compared
with NT alone from 3.25 ± 0.36 to 2.38 ± 0.34 sp/100 µm/s
(Figure and E). Spark morphology was unchanged
(see Supplementary material online, A–D).We predicted that the reduction in spontaneous Ca2+ sparks from
the SR in the presence of flecainide would result in a reduction in wave
frequency. In order to test this hypothesis, 5 Hz stimulation was used to
produce waves. There was a reduction in Ca2+ wave frequency in
the presence of flecainide (Figure ) from 0.23 ± 0.04 to 0.10
± 0.02 waves/s (P = 0.001). Since it has
previously been suggested that a prolonged period of flecainide loading is
required to produce SR Ca2+ release reduction,[9] we tested whether
prolonged exposure would have any additional effect. Thirty minutes of exposure
produced no further wave reduction compared to 5 mins (see Supplementary material online, ).Effects of 5 µM flecainide on Ca2+
waves. (A) Flecainide was washed on or off via
cross-over protocol for 5 min. In the presence of flecainide, wave
frequency was significantly reduced (P =
0.001, n = 20 cells). (B)
Latency period from the last transient to the first wave is shown in
the Kaplan–Meier survival format (i.e. wave-free survival).
Cells in the presence of flecainide have an increased wave-free
survival period (P = 0.002 by log-rank test,
n = 20 cells). (C) Wave
velocity is reduced in the presence of flecainide
(P = 0.04 by Student's
t-test, NT: n = 81
waves; flec: n = 36 waves from 20 cells).
(D) Representative line-scans from a cell
assessed for waves pre- and post-flecainide application. The end of
the 30 s period of 5 Hz stimulation evoking Ca2+
transients can be seen at the top of the scans with subsequent
quiescent phase during which waves are observed. Areas of increased
spark activity prior to waves are highlighted with white arrows and
are more prominent in the absence of flecainide. Inset: line-scans
converted into F/F0
plots—reduction of wave frequency and increased latency is
apparent.The time from the last transient to the first wave, defined as the
‘wave-free survival period’ for each cell, and represented in
Kaplan–Meier survival curve format in Figure , was also significantly
increased in the presence of flecainide. In addition, wave velocity was reduced
(Figure ) from 146.4 ± 4.7 to 130 ± 5.8 µm/s
(P = 0.04 by Student's
t-test), suggesting that wave propagation is also altered by
flecainide. Confocal line-scanning reveals both the reduction in
Ca2+ waves and how this is related to a reduction in spark
frequency (Figure ). Wave amplitude did not change significantly in the
presence of flecainide (see Supplementary material online, B).
Specific INa blockade decreases spark and wave
frequency
There are two broad mechanisms which may be responsible for the reduction in
Ca2+ waves in the presence of flecainide. First, by
blocking Ca2+ release from the RyR2, for which there is
conflicting evidence in CPVT myocytes,[9,10] and
second by inhibiting Na+ influx with subsequent downstream
effects. We aimed to assess the latter possibility—namely, whether SR
Ca2+ release can be altered by reducing
Na+ influx.We therefore assessed the effect of specific pharmacological inhibition of
INa using 5 µM tetrodotoxin (TTX), a dose
which was selected since it provides 25% INa
blockade in cardiomyocytes,[13] which is similar to that provided by 5 μM
flecainide,[14]
while still allowing Ca2+ transients to occur with external
field stimulation. Spark frequency was reduced (Figure ) from 3.76 ±
0.48 to 2.24 ± 0.52 sp/µm/s in the presence of TTX
(P = 0.009). TTX also significantly reduced wave
frequency (Figure ) and caused a reduction in wave velocity
(Figure ) without changing wave amplitude (see Supplementary material online, B). Similar to results with
flecainide, application of TTX at this concentration resulted in no significant
alteration of SR load (Figure ). To assess whether this was a general property of
other INa blockers, further experiments to assess
wave frequency under similar degrees of INa blockade
by 5 μM propafenone[15] and 200 μM lidocaine[16] were carried out. Both agents reduced
waves in a similar manner to flecainide and TTX (Figure and
F). Together, these results strongly suggest that
INa is involved in wave formation.Effects of INa inhibition by
tetrodotoxin (TTX), propafenone and lidocaine on SR
Ca2+ release events. (A) 5
µM TTX applied via similar cross-over protocol to flecainide
experiments induced a similar reduction in Ca2+
spark frequency (P = 0.009,
n = 14 cells). (B) 5
µM TTX reduced wave frequency (P =
0.0002, n = 10 cells). (C)
Wave velocity is significantly reduced in the presence of TTX
(P = 0.012 by Student's
t-test, NT: n = 84
waves; TTX: n = 34 waves from 10 cells).
(D) Similar to flecainide experiments, no
significant change in SR load was seen in the presence of 5
µM TTX (P = 0.97 by Student's
t-test, n = 20 cells
from three isolations). (E) 5 μM propafenone
reduced Ca2+ wave frequency in a similar manner
(P = 0.0007, n =
10 cells), as did (F) 200 μM lidocaine
(P = 0.0012, n =
10 cells).
How does INa reduction decrease
Ca2+ waves?
Two main possibilities could explain the involvement of
INa in wave formation. The first is that
Na+ entry via Nav1.5 channels alters the
sub-sarcolemmal ‘fuzzy’ space [Na+] which
subsequently modifies wave propagation via a number of possible downstream
mechanisms (Mechanism A, Figure ). The second is that Nav1.5
channel activation is involved in the process of wave initiation and propagation
more directly at the wave front (Mechanism B, Figure ).Possible hypotheses to explain how
INa can contribute to wave
initiation and propagation. (A) Entry of
Na+ ions occurs via
INa and an alteration of wave
properties may result from changes in
[Na+]i, particularly in the
sub-sarcolemmal space. In this proposed mechanism (1) increased
fuzzy space [Na+] provides a milieu that enhances
the probability of (2) Ca2+ sparks leading to (3)
the activation and firing of an adjacent RyR cluster to result in
(4) wave initiation and propagation throughout the cell.
(B) Alternatively Nav1.5 channels
may be involved in wave propagation per se in the
intact cardiomyocyte. Such involvement could comprise (1)
spontaneous SR Ca2+ release in the form of a spark
resulting in (2) local Ca2+ efflux by NCX causing
(3) local depolarization of the sarcolemma, which (4) subsequently
results in local activation of INa and
ICa assisting the rise in local
(‘fuzzy space’) [Ca2+]i
that can lead to (5) adjacent RyR clusters firing and (6) wave
propagation.If Mechanism A is accurate, then given its dependence on Na+
influx via Nav1.5, wave frequency should be reduced by an
intervention which reduces Na+ influx during the contraction
train but leaves Nav1.5 channels available during the quiescent
period following the contraction train. Such a scenario was created using a
voltage clamp technique to inactivate INa during the
stimulation train. Cells were stimulated by a 5 Hz train of clamp pulses (100 ms
in duration) from −80 to 0 mV repeatedly for 1 min and waves assessed
during a subsequent 30 s quiescent period when the cells were held at −80
mV. The same cell was re-stimulated by another train of pulses from −40
to 0 mV, thereby removing Na+ influx due to
INa inactivation. The final holding potential
during the quiescent period was −80 mV as before to ensure availability
of Nav1.5 channels (Figure ). There was a significant reduction in
wave frequency from 0.30 ± 0.04 to 0.16 ± 0.03 waves/s following
inactivation of INa by voltage clamp
(Figure ), suggesting greater importance of Mechanism A.Elucidation of Mechanism A as most likely cause for reduction in
Ca2+ waves due to
INa blockade. (A)
Voltage clamp stimulation trains used to assess wave frequency with
and without INa activity. Stimulation
was induced by stepping from −80 to 0 mv
(INa active) or −40 to 0 mV
(INa inactive). Pulse duration was
100 ms and pulses were applied at 5 Hz. Waves were assessed in a
subsequent 30 s interval during which membrane potential was held at
−80 mV. (B) With
INa inactive during the stimulation
train (but available during the quiescent phase of the experiment),
wave frequency was reduced (P = 0.002,
n = 7 cells). (C)
High-dose (50 µM) TTX was rapidly applied to cells to
terminate stimulation following a period of external field
stimulation at 5 Hz and compared with the control arm in which
stimulation was terminated in the usual fashion at 30 s (see Supplementary material online, for further explanation). This produced
the opposite situation to the previous experiment with
INa active during the stimulation
train but Nav1.5 channels unavailable for stimulation
during the quiescent phase. This produced no change in wave
frequency (P = 0.99, n
= 17 cells). (D) Similarly, there was no
change in wave velocity (P = 0.66 by
Student's t-test. Control:
n = 88 waves; 50 µM TTX:
n = 89 waves from 17 cells).
(E) Voltage clamp experiments showing effects
of flecainide on wave frequency with INa
active vs. inactive. With INa active,
flecainide reduces wave frequency (P =
0.001, n = 7 cells). (F)
However, with INa inactive, no reduction
in wave frequency was observed (P = 0.36,
n = 7 cells).To confirm these findings and assess whether Mechanism B might also be playing a
role, we designed an experiment which would allow normal Na+
influx during the contraction train but would profoundly reduce availability of
Nav1.5 channels during the quiescent phase. A stimulation train
was induced by external field stimulation for 30 s at 5 Hz and waves were
assessed as before in the control condition (NT + vehicle). The same cell
was then exposed to the same protocol but high-dose TTX (50 µM TTX, which
blocks >95% of INa[13]) was superfused over
cells rapidly after 30 s stimulation in NT to stop the contraction train. This
caused contractions and stimulated Ca2+ transients to cease
almost immediately despite continuation of field stimulation at the same voltage
(see Supplementary material online, ).
This provided evidence of Nav1.5 blockade during the quiescent period
while ensuring the SR loading protocol was identical. Results of these
experiments showed that acute, profound Nav1.5 blockade did not alter
Ca2+ wave frequency or velocity
(Figure and D), suggesting that Mechanism B
either does not occur or is of relatively minor importance compared with
Mechanism A.
Mechanism of wave reduction with flecainide
Having shown that INa reduction during the
contraction train can reduce the frequency and velocity of
Ca2+ waves, we wished to assess whether this effect also
played a role in the effects we had observed with flecainide. We first assessed
whether, in the absence of INa, flecainide would
still reduce wave frequency—potentially through an additional effect on
the RyR2. In order to test this possibility, we performed voltage clamp
experiments. With a stimulation train of voltage clamp steps from −80 to
0 mV, as expected, there was a significant reduction in Ca2+
waves (Figure ) in the presence of flecainide. However, when the
stimulation train was induced by voltage steps from −40 to 0 mV (and so
INa was inactivated), there was no significant
reduction in Ca2+ wave frequency (Figure ) in the presence of
flecainide. This provided evidence that reduced Na+ influx was
crucial in flecainide's mechanism of wave reduction.To investigate how the changes in Na+ influx into the cytosol
altered wave frequency, we identified two possibilities that we felt were most
likely to be the cause of the change. First, a reduction in
Ca2+/calmodulin-dependent protein kinase II (CamKII)
activity as a result of reduced [Na+]i[17] or
[Ca2+]i, and second as a result of enhanced
Ca2+ efflux across the sarcolemma via NCX because of an
enhanced [Na+]o:[Na+]i
gradient.In order to investigate the former possibility, we used 1 μM KN-93 to
inhibit CamKII prior to the addition of flecainide. In the presence of either
KN-93 (Figure ) or KN-92 (see Supplementary material online, A), flecainide remained able to
reduce Ca2+ wave frequency.Role of CaMKII and NCX in wave reduction by flecainide.
(A) Despite incubation of cells with 1
μM CaMKII inhibitor KN-93, flecainide was still able to
significantly reduce Ca2+ wave frequency.
Magnitude of reduction was similar in the presence of inactive
analogue KN-92 (see Supplementary material online, A), suggesting CaMKII
inhibition is not the mechanism of wave reduction with flecainide.
(B) NCX function in terms of
Ca2+ efflux efficacy was significantly
improved following a 5 Hz contraction train in the presence of
flecainide. (C) Direct partial inhibition of NCX by
1 mM Ni2+ applied after the contraction train
increased Ca2+ wave frequency.
(D) Reduction of
[Na+]o after the contraction train
can reverse the reduction in wave frequency seen with flecainide.
(E) Pooled data from experimental protocol
shown in (D) revealing that a reduction in wave
frequency induced by flecainide can be reversed by reducing
[Na+]o to 125 mM.
(F) 0.5 μM veratridine can increase
Ca2+ wave frequency via enhancing
INa. This effect was abolished by
increasing [Na+]o from 115 to 140
mM.We subsequently assessed NCX function by observing the rate constant of
Ca2+ efflux following a caffeine transient in NT under the
same conditions as waves were assessed (see Supplementary material online). There was a significant
increase in Ca2+ efflux via NCX following a contraction train
in the presence of flecainide (Figure ). We subsequently assessed how such
efflux would affect diastolic [Ca2+]i in the period
following the last field-stimulated contraction and the first
Ca2+ wave, using the ratiometric dye fura-2. We found that
there was a significant reduction in diastolic Ca2+ by
12% (P = 0.005, see Supplementary material online, B).In order to assess whether the opposite effect would occur with the inhibition of
Ca2+ efflux via NCX, we assessed the effects of partial
NCX inhibition[18] with 1
mM NiCl2 following the contraction train and found an increase in
waves (Figure ). Flecainide enhances Ca2+ efflux via
a reduction of [Na]i, enhancing the
[Na+]o:[Na+]i
gradient; however, this gradient can also be altered by changing
[Na+]o. We sought to do this in the presence of
flecainide to reverse the reduction in wave frequency. We found that a reduction
of [Na+]o after the contraction train from 140 to
125 mM was sufficient to reverse the wave reduction seen with flecainide
(Figure and E). In order to ascertain whether
the opposite effects would occur with INa
enhancement, we assessed whether 0.5 μM veratridine could increase
Ca2+ wave frequency. There was a significant increase in
waves in the presence of veratridine which was reversed by increasing
[Na]o from 115 to 140 mM.
Discussion
Main findings
The main finding of this study is that a reduction of
INa can reduce the frequency of
Ca2+ sparks and waves and the velocity of
Ca2+ waves. This holds true whether
INa is pharmacologically reduced by a variety of
agents or reduced by voltage clamp techniques. Initially, we wished to clarify
whether this occurred via altering the intracellular ionic milieu (Mechanism A,
Figure ) or whether Na+ influx was involved in
the process of wave propagation itself (Mechanism B, Figure ). A series of
experiments inactivating INa either during the
stimulation train or the quiescent phase (Figure ) confirmed that a
reduction in Na+ influx is the most important mechanism
involved in reducing Ca2+ waves rather than implicating a role
for Nav1.5 channels at the Ca2+ wave front. In
further support of the importance of changes of cytosolic ionic milieu is the
fact that very different INa blockers including the
neurotoxin TTX, class 1c drugs flecainide and propafenone, and the class 1b drug
lidocaine produce a similar reduction in Ca2+ wave frequency
when concentrations producing similar degrees of INa
blockade are used.We used voltage clamp to assess whether a reduction in
INa was crucial for this effect. In the absence
of INa, flecainide is not able to reduce
Ca2+ waves, suggesting dominance of this mechanism over
RyR2 blockade under our conditions.The question of how the alteration in cellular ionic milieu reduces
Ca2+ waves is complex and may be multifactorial. A
reduction in [Na+]i is expected to increase
[Ca2+] efflux across the sarcolemma via NCX and so there
is additional complexity since both [Na+]i and
[Ca2+]i may be altered. We went on to
investigate how such changes contribute to wave reduction.
Mechanism of wave reduction does not depend on CaMKII
First, Ca2+/calmodulin complex (CaMKII), a major regulator of
SR Ca2+ leak,[19] is affected both by
[Ca2+]i and directly by
[Na+]i.[17] We investigated the efficacy of
flecainide in Ca2+ wave reduction in the presence of KN-93, an
inhibitor of CaMKII, and its inactive analogue KN-92. Wave reduction still
occurred in the presence of either compound. In addition, the efficacy of wave
reduction was unchanged whether KN-93 or KN-92 was present (35 vs. 37%
reduction, respectively), suggesting that CaMKII inhibition does not have a
major role in wave reduction due to INa
inhibition.
Wave reduction does not result from reduced SR Ca2+
load
Another major possibility was that reduced [Na+]i
resulted in enhanced Ca2+ efflux via NCX. This has the
potential to decrease SR luminal [Ca2+]; however, we found
that neither 5 µM flecainide nor 5 μM TTX had significant effects
on SR Ca2+ content. This is consistent with the work of
previous investigators using similar doses of flecainide.[9,10] Altered NCX function could reduce waves
by mechanisms unrelated to SR load, however. For example, let us assume that
almost maximal SR load was produced by our experimental conditions in the rat
species, and that a tightly controlled SR luminal Ca2+
threshold exists beyond which sparks and waves occur. In this case, if
INa blockade enhances Ca2+
efflux via NCX, then SR load may reach threshold for spark and wave release less
frequently since the SR Ca2+-ATPase would have more
competition for Ca2+ ions in the fuzzy space. Since the
threshold per se would not change in this situation (no RyR2
modification), one may not observe lower SR load but simply less frequent SR
Ca2+ release.
INa reduction increases Ca2+
efflux via NCX, which reduces Ca2+ waves
We performed experiments to assess the possibility of an NCX-mediated effect on
Ca2+ waves despite the absence of SR
Ca2+ load reduction. We assessed NCX function using the
decay constant of NCX-mediated [Ca2+]i decline in
the presence of caffeine and confirmed that Ca2+ efflux via
NCX was increased after a contraction train in the presence of flecainide
(Figure ). This resulted in a slight reduction in diastolic
[Ca2+]i in the quiescent period following our
contraction train as assessed by fura-2 fluorescence (see Supplementary material online, B). In order to confirm the relevance
of this mechanism, we modulated NCX function in other ways. Direct partial
inhibition of NCX[18] with
1 mM Ni2+ applied after the contraction train increased
Ca2+ waves (Figure ), suggesting that NCX is functioning
predominantly in the inward mode under our experimental conditions. Impairing
NCX increases waves by reducing Ca2+ efflux. This helps to
clarify how INa blockade might reduce
Ca2+ waves. In the presence of lower
[Na+]i, NCX would provide more effective
Ca2+ efflux at resting membrane potentials.[20] On the other hand, a
lower [Na+]o would shift the reversal potential of
NCX in the negative direction. As such, if altered NCX function resulting from
reduced [Na+]i was the cause of wave reduction in
the presence of flecainide, we expected that such an effect could be abrogated
by a reduction in [Na+]o. Indeed, we found that
reducing [Na+]o from 140 to 125 mM in the period
following the contraction train completely reversed the reduction in
Ca2+ waves seen with flecainide
(Figure ).Finally, we provide evidence that an increase in INa
can increase Ca2+ wave frequency, using the Nav1.5
channel activator veratridine (Figure ). The subsequent reduction in wave
frequency by increasing [Na]o shows that increasing
Ca2+ efflux via NCX can reverse this effect.Direct blockade of NCX function using a selective NCX blocker may have been a
useful approach to highlight the importance of
[Na+]i on waves. However, most NCX blockers
have off-target effects. Even when these are limited, such as in the case of
SEA-0400, they still produce a reduction of ICa via
intracellular accumulation of Ca2+ which causes inhibition of
the L-type Ca2+ current via Ca2+-dependent
inactivation.[21]
Hence, it was felt that direct NCX blockade with small molecule inhibitors may
yield results that could be more difficult to interpret than modulating NCX
function via alterations in [Na+]o to counteract
the changes in
[Na+]o:[Na+]i
gradient caused by INa blockade.
INa blockers and SR Ca2+
release
Although it is accepted that Na+ influx can, via subsequent
efflux by NCX, cause Ca2+ entry and generation of contractile
force,[22] and
even that Ca2+ entry via the exchanger can induce
Ca2+ sparks,[23] NCX has been largely neglected in the investigation of
how INa inhibitors can reduce SR
Ca2+ release. This is largely because, at high
concentrations (e.g. 20 μM flecainide), some
INa inhibitors have direct effects on RyR2 in
permeabilized cells and lipid bilayer experiments.[7-9] It is not possible to compare our experiments directly
with such previous work since ventricular myocytes from mouse models of CPVT
were used. In these studies, contrasting results were presented, with Knollman
and co-workers[7,9] reporting a reduction in
wave frequency but increased spark frequency in both intact
Casq−/− and permeabilized normal rat ventricular myocytes and Liu
et al.[10] finding no changes in sparks or waves with flecainide in
either intact or permeabilized ventricular cardiomyocytes from
RyR2R4496C+/− mice.This inconsistency led us to investigate further despite the provision by
Knollman and co-workers[7,9]' of multiple lines
of evidence that RyR2 inhibition rather than altered Na+ flux
is the predominant mechanism of action in their experiments. In contrast, we
find that without an active Na+ current, no reduction in waves
can be observed with flecainide. In addition, reduction in
INa alone, via various pharmacological agents
and voltage clamp techniques, is sufficient to cause a reduction in wave
frequency via enhancement of Ca2+ efflux by NCX. Contributory
to the differences between our work and other studies may be: (i) species
difference and lack of CPVT model in our experiments; (ii) use of
supra-therapeutic flecainide concentrations to obtain effects in permeabilized
cells and lipid bilayer experiments by Knollman and co-workers while we used a
therapeutically relevant concentration throughout; and (iii) lack of paired data
in other studies which may reduce the power to detect differences in wave
frequency (perhaps explaining the lack of efficacy seen with alternative
INa blockers such as TTX and lidocaine by Hwang
et al.[24]).
Limitations
Rapid application of caffeine is a well-accepted technique to assess SR load but
may be insensitive to subtle changes in store Ca2+ content. We
attempted to minimize inaccuracies by using a ratiometric dye and applying
caffeine in the presence of
Na+-free/Ca2+-free solution to obtain an
accurate peak [Ca2+]i.Our voltage clamp trains from −80 to 0 mV vs. −40 to 0 mV, designed
to eliminate INa, could also alter NCX function
during the contraction train; however, this would promote Ca2+
entry at −40 vs. −80 mV and thus increase Ca2+
waves rather than reduce them. Hence, this is not responsible for the reduction
in wave frequency in the absence of INa.
Conclusions
Reducing Na+ influx during contraction in the intact
cardiomyocyte reduces spontaneous diastolic SR Ca2+ release
both in the form of Ca2+ sparks and waves. Given that SR load
is unchanged, this is the result of reduced [Ca2+]i
in the vicinity of the RyR2 (due to enhanced efflux via NCX), which reduces the
open probability of the channel. In the intact rat cardiomyocyte, this is the
predominant mechanism of action for the reduction in Ca2+
waves seen with flecainide at therapeutic concentrations. Other means of
reducing Na+ influx, such as INa,L
reduction, would be expected to reduce SR Ca2+ leak via
similar mechanisms.
Supplementary material
Supplementary material is available at .Conflicts of interest: none declared.
Funding
This work was primarily funded by the Wellcome Trust (WT092852) and the British Heart
Foundation (PG/11/87/29158). ARL is supported by a British Heart Foundation
Intermediate Research Fellowship (FS/11/67/28954) and the National Institute for
Health Research-funded Cardiovascular Biomedical Research Unit at the Royal Brompton
Hospital. Open access funding is jointly provided by the Wellcome Trust and the
British Heart Foundation.
Authors: Robert Larbig; Natalia Torres; John H B Bridge; Joshua I Goldhaber; Kenneth D Philipson Journal: J Physiol Date: 2010-07-19 Impact factor: 5.182
Authors: Qiang Zhou; Jianmin Xiao; Dawei Jiang; Ruiwu Wang; Kannan Vembaiyan; Aixia Wang; Chris D Smith; Cuihong Xie; Wenqian Chen; Jingqun Zhang; Xixi Tian; Peter P Jones; Xiaowei Zhong; Ang Guo; Haiyan Chen; Lin Zhang; Weizhong Zhu; Dongmei Yang; Xiaodong Li; Ju Chen; Anne M Gillis; Henry J Duff; Heping Cheng; Arthur M Feldman; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen Journal: Nat Med Date: 2011-07-10 Impact factor: 53.440
Authors: Nian Liu; Marco Denegri; Yanfei Ruan; José Everardo Avelino-Cruz; Andrea Perissi; Sara Negri; Carlo Napolitano; William A Coetzee; Penelope A Boyden; Silvia G Priori Journal: Circ Res Date: 2011-06-16 Impact factor: 17.367
Authors: Michael Ritter; Zhi Sui; Kenneth D Philipson; Fenghua Li; Kenneth W Spitzer; Hideyuki Ishida; William H Barry Journal: Cell Calcium Date: 2003-07 Impact factor: 6.817
Authors: Hiroshi Watanabe; Nagesh Chopra; Derek Laver; Hyun Seok Hwang; Sean S Davies; Daniel E Roach; Henry J Duff; Dan M Roden; Arthur A M Wilde; Björn C Knollmann Journal: Nat Med Date: 2009-03-29 Impact factor: 53.440
Authors: Pei-Chi Yang; Jonathan D Moreno; Mao-Tsuen Jeng; Xander H T Wehrens; Sergei Noskov; Colleen E Clancy Journal: J Physiol Date: 2016-11-01 Impact factor: 5.182
Authors: Mohamed Y Amarouch; Heikki Swan; Jaakko Leinonen; Annukka Marjamaa; Annukka M Lahtinen; Kimmo Kontula; Lauri Toivonen; Elisabeth Widen; Hugues Abriel Journal: Ann Noninvasive Electrocardiol Date: 2015-10-07 Impact factor: 1.468
Authors: Przemysław B Radwański; Lucia Brunello; Rengasayee Veeraraghavan; Hsiang-Ting Ho; Qing Lou; Michael A Makara; Andriy E Belevych; Mircea Anghelescu; Silvia G Priori; Pompeo Volpe; Thomas J Hund; Paul M L Janssen; Peter J Mohler; John H B Bridge; Steven Poelzing; Sándor Györke Journal: Cardiovasc Res Date: 2014-12-23 Impact factor: 10.787